Endoscopic ultrasound-guided portal vein sampling and circulating tumor cells: the next frontier in pancreatic cancer, or a step too far?

Endoscopy 2025; 57(08): 910-911
DOI: 10.1055/a-2563-0211

Editorial

Referring to Prasoppokakorn T et al. doi: 10.1055/a-2535-7440

¹Pancreatobiliary Endoscopy and Endosonography Division, IRCCS San Raffaele Scientific Institute, Milan, Italy

References
1 Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74: 12-49
2 Pang TCY, Po JW, Becker TM. et al. Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. Pancreatology 2021; 21: 103-114
3 Prasoppokakorn T, Chaiteerakij R, Buntho A. et al. Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I–III pancreatic ductal adenocarcinoma. Endoscopy 2025;
4 Zhang Y, Su H, Wang H. et al. Endoscopic ultrasound-guided acquisition of portal venous circulating tumor cells as a potential diagnostic and prognostic tool for pancreatic cancer. Cancer Manag Res 2021; 13: 7649-7661
5 Chapman CG, Ayoub F, Swei E. et al. Endoscopic ultrasound acquired portal venous circulating tumor cells predict progression free survival and overall survival in patients with pancreaticobiliary cancers. Pancreatology 2020; 20: 1747-1754
6 Catenacci DVT, Chapman CG, Xu P. et al. Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound. Gastroenterology 2015; 149: 1794-1803 e4